Two-year clinical outcomes after discontinuation of long-term golimumab therapy in Korean patients with rheumatoid arthritis
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- KCISCIEScopus
- 저널 순위
- JCR Q2Scopus Q2KCI Q3
- 저널
- KOREAN JOURNAL OF INTERNAL MEDICINE37(5) · pp.1061 · 2022
- 피인용
- Web of Science 0Scopus 0KCI 0
- FWCI (Scopus)
- 0
- JCR IF
- JCR 2021 3.165
- ISSN
- 1226-3303
저자
- Shin, Kichul제1저자Seoul Natl Univ, Div Rheumatol, Seoul Metropolitan Govt, Boramae Med Ctr, Seoul, South Korea
- Kwon, Hyun MiSeoul Natl Univ Hosp, Dept Internal Med, Div Rheumatol, Seoul, South Korea
- Kim, Min JungSeoul Natl Univ, Div Rheumatol, Seoul Metropolitan Govt, Boramae Med Ctr, Seoul, South Korea
- Yoon, Myung JaeSeoul Natl Univ Hosp, Dept Internal Med, Div Rheumatol, Seoul, South Korea
- Chai, Hyun GyungSeoul Natl Univ Hosp, Dept Internal Med, Div Rheumatol, Seoul, South Korea
- Kang, Seong-WookChungnam Natl Univ Hosp, Div Rheumatol, Daejeon, South Korea
- Park, WonInha Univ Hosp, Div Rheumatol, Incheon, South Korea
- Park, Sung-HwanCatholic Univ Korea, Coll Med, Div Rheumatol, Seoul St Marys Hosp, Seoul, South Korea
- Suh, Chang HeeAjou Univ Hosp, Div Rheumatol, Suwon, South Korea
- Kim, Hyun AhHallym Univ, Div Rheumatol, Sacred Heart Hosp, Anyang, South Korea
- 이승근Pusan Natl Univ Hosp, Div Rheumatol, Busan, South Korea
- Lee, Choong KiYeungnam Univ, Div Rheumatol, Med Ctr, Daegu, South Korea
- Bae, Sang-CheolHanyang Univ, Div Rheumatol, Seoul Hosp, Seoul, South Korea
- Park, Yong-BeomYonsei Univ, Severance Hosp, Div Rheumatol, Coll Med, Seoul, South Korea
- Song, Yeong Wook교신저자Seoul Natl Univ Hosp, Dept Internal Med, Div Rheumatol, Seoul, South Korea
초록
Background/Aims: The aim of this study was to investigate long-term post -discontinuation outcomes in patients with rheumatoid arthritis (RA) who had been treated with tumor necrosis factor-alpha inhibitors (TNF-alpha i) which was then discontinued. Methods: Sixty Korean patients with RA who participated in a 5-year GO-BEFORE and GO-FORWARD extension trials were included in this retrospective study. Golimumab was deliberately discontinued after the extension study (baseline). Patients were then followed by their rheumatologists. We reviewed their medical records for 2 years (max 28 months) following golimumab discontinuation. Patients were divided into a maintained benefit (MB) group and a loss-of-benefit (LB) group based on treatment pattern after golimumab discontinuation. The LB group included patients whose conventional disease-modifying antirheumatic drug(s) were stepped-up or added/switched (SC) and those who restarted biologic therapy (RB). Results: The mean age of patients at baseline was 56.5 years and 55 (91.7%) were females. At the end of follow-up, 23 (38.3%) patients remained in the MB group. In the LB group, 75.7% and 24.3% were assigned into SC and RB subgroups, respectively. Fifty percent of patients lost MB after 23.3 months. Demographics and clinical variables at baseline were comparable between MB and LB groups except for age, C-reactive protein level, and corticosteroid use. Restarting biologic therapy was associated with swollen joint count (adjusted hazard ratio [HR], 1.90; 95% confidence interval [CI], 1.01 to 3.55) and disease duration (adjusted HR, 1.12; 95% CI, 1.02 to 1.23) at baseline. Conclusions: Treatment strategies after discontinuing TNF-alpha i are needed to better maintain disease control and quality of life of patients with RA.
키워드
ArthritisrheumatoidGolimumabBiological therapyAntirheumatic agentsLOW-DISEASE-ACTIVITYADALIMUMAB PLUS METHOTREXATEMONOCLONAL-ANTIBODYNAIVE PATIENTSDOUBLE-BLINDREMISSIONMULTICENTERMONOTHERAPYETANERCEPTINFLIXIMAB
식별자
- Scopus EID
- 2-s2.0-85137745885
- WoS UID
- 000737497000001
- KCI
- ART002868627



로그인
연구물 목록으로